Coreline Soft Unveils Revolutionary AVIEW for Lung Cancer Screening at ECR 2025

Innovative Lung Cancer Screening with AI

Coreline Soft, a leading player in medical AI, is set to showcase its groundbreaking AVIEW platform at the European Congress of Radiology (ECR) 2025, taking place in Vienna from February 26 to March 2. As Europe's largest radiology congress, ECR draws radiologists and medical device companies from around the globe, presenting a prime opportunity for innovative solutions in healthcare.

The focus of this year's presentation will be on the all-new AVIEW, especially the flagship product, AVIEW (LCS Plus), renowned for its capabilities in lung cancer screening. Coreline Soft has already been involved in various lung cancer screening initiatives across Europe, demonstrating the significant impact of its AI technologies in managing cloud-based imaging data. With the introduction of its next-generation AVIEW, the company aims to streamline and enhance the workflow in lung cancer screening, set to expand its reach within the European medical market.

Enhanced Features and Functionality

The upgraded AVIEW platform emphasizes optimization in efficiency, security, and stability. Users can expect a refined interface focused on user experience (UX) and user interface (UI), supporting seamless communication among health professionals. Coreline Soft believes these advancements are critical at a time when automated workflows and innovative AI solutions possess a competitive edge in the healthcare field.

Coreline Soft's past involvement in significant projects such as the European Lung Cancer Detection Project (4ITLR), German Lung Cancer Screening (HANSE), and Italian Detection Programs (RISP) showcases its capability. This extensive collaboration with leading institutions underscores the potential of AVIEW to redefine lung cancer detection paradigms significantly.

Regulatory Milestones and Future Plans

Recently, Germany has set a precedent by endorsing AI as a primary diagnostic tool in lung cancer screening, with similar movements noted in countries like France. In light of this, the European Journal of Cancer published findings indicating the efficacy of AVIEW LCS in screening processes. Coreline Soft is keen to leverage these developments to facilitate the broader implementation of AI-driven diagnostic solutions throughout Europe.

Comments from Jason (Junghyuck) Suh, the Foreign Business Director at Coreline Soft, emphasize their commitment to complying with rigorous standards, such as the General Data Protection Regulation (GDPR), as they expand their presence in the global market. The avowed motive behind the new AVIEW launch is not just to maintain a leading role but also to integrate speed, precision, and collaborative features into lung cancer screening practices across Europe.

Looking Ahead

As Coreline Soft prepares for ECR 2025, the anticipation surrounding AVIEW is palpable. With the urgent need for reliable and effective lung cancer screening solutions growing, the launch of AVIEW is timely, promising an innovative approach to a pressing health challenge. The upcoming congress will serve as an essential platform for Coreline Soft to unveil its transformative solution and make significant inroads into the European healthcare landscape, showcasing its commitment to improving cancer detection and patient outcomes.

In conclusion, Coreline Soft’s journey through ECR 2025 will significantly shape the future of lung cancer screening, reaffirming the company's role as a leader in AI-driven healthcare solutions. As the next phase unfolds, healthcare professionals and organizations across Europe eagerly await the full integration of AVIEW into their screening processes, potentially leading to earlier detection and better patient care.